OasisLMS

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 15 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ACCME Activity ID 202590840

Date of Release: December 2, 2024
Date of Termination: December 1, 2027

No commercial support was received for this activity.

Agarwal, Monica , MD, MEHP, FACE: No Relevant Financial Relationships

Courcoulas, Anita, MD, MPH, FACS: Researcher relationship with Allurion Technologies (Medical Device) and Eli Lilly (Pharmaceuticals). Fox, Claudia, MD, MPH Independent Contractor relationship with Novo Nordisk (Pharmaceuticals) and Eli Lilly (Pharmaceuticals).

Gilden, Adam, MD, MSCE: No Relevant Financial Relationships

Heinberg, Leslie, PhD: Researcher relationship with Weight Watchers (Medical Food and Weight Management*).

Horn, Deborah, DO, MPH: Consultant relationship with Eli Lilly (Pharmaceuticals), Gelesis (Pharmaceuticals), Novo Nordisk (Pharmaceuticals). Researcher relationship with Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals). Speaker relationship with Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals).

Jakicic, John, PhD, FTOS, FACSM: Consulting Fee relationship with Wondr Health (Weight Management*). Consultant relationship with Education Initiatives, Inc. (Weight Management*). Researcher relationship with Epitomee Medical, Inc. (Medical Device).

Jensen, Michael, MD: Advisor relationship with Seattle Gummy (Supplement). Consultant relationship with Biohaven (Pharmaceuticals) and Medality Medical, Inc. (Medical Device). Researcher relationship with Novo Nordisk (Pharmaceuticals).

Katzmarzyk, Peter, PhD: No Relevant Financial Relationships

Perreault, Leigh, MD: Advisor relationship with Boehringer Ingelheim (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). Speaker relationship with Bayer (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Elli Lilly (Pharmaceuticals), Janssen (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Sanofi (Pharmaceuticals).

Purnell, Jonathan, MD, FTOS, Dipl. ABOM: Advisor relationship with Boehringer Ingelheim (Pharmaceuticals), Luciole Pharmaceuticals (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), Regeneron (Pharmaceuticals).

Sheer, Amy, MD, MPH, Dipl. ABOM: Speaker relationship with Eli Lilly (Pharmaceuticals).

Agarwal, Monica , MD, MEHP, FACE: No Relevant Financial Relationships

Purnell, Jonathan, MD, FTOS, Dipl. ABOM: Advisor relationship with Boehringer Ingelheim (Pharmaceuticals), Luciole Pharmaceuticals (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), Regeneron (Pharmaceuticals).

No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

1. Endo Text, Obesity subsection (https://www.endotext.org/section/obesity/)— edited by Jonathan Q Purnell, Blandine Laferrère, and Nitin Kapoor, MD, DM, PhD
2. Handbook of Obesity, 5th edition (2023) – Volumes 1 and 2 – edited by George Bray and Claude Bouchard.
3. The ASMBS Textbook of Bariatric Surgery, 2nd edition (2020) – edited by Ninh T. Nguyen, Stacy A. Brethauer, John
M. Morton, Jaime Ponce, Raul J. Rosenthal
4. Pediatric Obesity: Etiology, Pathogenesis, and Treatment, 2nd edition (2018) – edited by Michael Freemark

5. Primary Care: Evaluation and Management of Obesity, 1st edition (2022) – edited by Robert Kushner, Daniel Bessesen, Adam Gilden